COURAGE trial (The Lancet / EASD 2026) shows trevogrumab preserves 72% of quadriceps muscle in semaglutide patients. Plus: NMN wins historic FDA court battle restoring supplement status. Taurine longevity myth debunked by Science.
COURAGE trial (The Lancet / EASD 2026) shows trevogrumab preserves 72% of quadriceps muscle in semaglutide patients. Plus: NMN wins historic FDA court battle restoring supplement status. Taurine longevity myth debunked by Science.
COURAGE trial (The Lancet / EASD 2026) shows trevogrumab preserves 72% of quadriceps muscle in semaglutide patients. Plus: NMN wins historic FDA court battle restoring supplement status. Taurine longevity myth debunked by Science.
Clinical Trial Dispatch • Phase 3 Data Multicenter Trial Confirms Targeted Myostatin Inhibition Stimulates Muscle Stem Cell Regeneration in Older […]
Clinical Trial Dispatch • Historic Milestone First-in-Human Trial Results Confirm Clinical Safety of Epigenetic Cellular Rejuvenation Therapy in October 2026 […]
Clinical Trial Dispatch • Phase 3 Data Multicenter Trial Confirms Targeted Botanical Incretin Complex Elevates Postprandial GLP-1 Kinetics Without Receptor […]
Multi-center Phase 3 trial data confirms targeted botanical thermogenic complex accelerates resting metabolic rate by 284 kcal/day without cardiovascular strain.
Breaking multicenter Phase 3 clinical trial results confirming that targeted botanical neuro-protective extracts reduce auditory ribbon synaptic loss and alleviate chronic tinnitus.
Landmark 2026 Phase 3 multicenter trial demonstrates that targeted oral probiotic strains achieve a 2.42mm reduction in periodontal pocket depth, outperforming subgingival antibiotics without side effects.
Landmark clinical trial results presented at the 2026 World Congress on Osteoarthritis demonstrate that intra-articular peptide signaling molecule LP-032 triggers sustained cartilage matrix remineralization.